Synthesis of natriuretic peptides and immune activation represents an important part of the neurohumoral response to heart failure. Brain type natriuretic peptide is released primarily from the ventricles in response to myocyte stretch. It is synthesized as an inactive prohormone that is split into active hormone BNP and the inactive N-terminal fragment (NT-proBNP). BNP has a number of systemic effects, including vasodilation, increased sodium excretion and urinary volume, inhibition of the renin-angiotensin-aldosteron system and sympathetic nervous system (6, 10, 19, 20) . The main pathological process resulting in increased synthesis and the BNP release and NT-proBNP is impairment of left ventricular systolic or diastolic function (2, 11, 18) . The plasma NT-proBNP is also an independent prognostic factor (1, 8, 12, 13, 21) . Therefore, the assessment of natriuretic peptides has been implemented into the ESC and AHA/ACC guidelines for diagnosis and management of heart failure (9,16).
The investigation conforms with the principles outlined in the Declaration of Helsinki and has been approved by the Ethical Committee of our institution. All patients provided informed consent prior to participation.
Control group
All healthy individuals [mean (SD) age 47 (17) years, 12 women and 14 men, 4 were over 50 years old] were nonobese, normotensive, and free from acute diseases, and they all denied the use of any drugs during the 4 weeks before the study. They all had normal plasma values for the main plasma indices and, as well as non-pathologic erythrocyte and leukocyte counts and urine analysis. In all of the participants a complete cardiologic examination, including electrocardiogram and echocardiographic investigation (left ventricular ejection fraction >55 %), was performed. In the subjects >50years of age, an effort stress test (bicycle ergometry) was performed to exclude asymptomatic heart disease. Cardiac morphology and function were assessed by echocardiography. The control group was recruited from the people examined in our department in preventive programmes.
Blood specimen collection and analysis
Venous blood samples were obtained after 30 minutes of supine rest position from an indwelling catheter immediately after admission. Blood samples were collected in chilled tubes containing EDTA, immediately placed on ice, and promptly centrifuged. After centrifugation, the plasma was decanted and stored at -20 °C until assayed.
Plasma NT-proBNP concentrations were determined by using electrochemiluminiscence sandwich immunoassay (Roche Diagnostics). The assay was performed on the Elecsys System 1010 by the same analyst, who followed the assay manufacturer's recommendations.
Echocardiography
The transthoracic echocardiography was performed on each patient by the same operator, who was blinded to the humoral data. The measurements for M-mode guided calculation of left ventricular mass (LVM, left ventricular internal end-systolic and end-diastolic dimensions (LVIDs and LVIDd, respectively), interventricular septal wall thickness (IVST), left ventricular posterior wall thickness (PWT), right ventricular internal dimension (RVID) and left atrium diameter (LAD) were performed according to the guidelines of the American Society of Echocardiography (17) . Left ventricular mass (LVM) was calculated according to the Devereux formula and indexed to body surface area (7) . The presence of left ventricular hypertrophy (LVH) was defined on the basis of an LVMI greater than > 134 g/m 2 body surface area in men or > 110 g/m 2 body surface area in women. For the measurement of IVC diameter, the patients were scanned in the supine position, and the IVC was visualized by a subcostal approach. The diameter was measured within 2 cm of the right atrium origin of IVC. In cases when the IVC diameter was not stable through pulsation, the diameter was determined by using maximum values of IVC diameter of M-mode technique. Because of acute settings in acute intensive care department, the respiratory variations were not measured.
Cardiothoracic ratio
Cardiothoracic ratio (CTR) was assessed as the ratio between the maximal transverse diameter of the heart, and the maximal diameter of the thoracic cage, as measured on an AP chest radiograph.
Statistical analysis
Data are presented as mean ± SD or as median. Clinical characteristics and haemodynamic data of study population are presented as percentages of dichotomous variables and means ± SD for continuous variables. Linear regression analysis was performed to assess the relation between plasma NT-proBNP and clinical parameters. Pearson's rank correlation test was performed to evaluate the relationship between NT/proBNP and clinical variables. Potential confounding factors that might significantly contribute to NTproBNP elevation were evaluated by the use of multiple regression analysis.
Results

Demographic and clinical characteristics
of the study population (Tab. 1, 2) The most common cause of heart failure in the study population was chronic coronary artery disease; the majo- Data are expressed as mean and SD or in percents, CAD = coronary artery disease, LDL-C = low density cholesterol, SBP=systolic blood pressure, DBP=diastolic blood pressure, HR=heart rate.
Tab. 1:
Clinical characteristics and haemodynamic data of the patients at the time of admission. rity of these patients had previous myocardial infarctions. Eighty percent of all patients had at least three risk factors. The mean age for the entire group of patients was significantly higher vs. controls (68 ± 11 vs. 47 ± 17 years, p< 0.001). Nine patients were admitted with clinical symptoms of lung oedema, six patients with cardiogenic shock. Fourteen patients died despite the therapy.
Plasma NT-proBNP levels, Killip class, cardiothoracic ratio (Tab. 2) and plasma creatinine level The mean plasma NT-proBNP level of the group of all patients was significantly elevated (8 000 ± 9 000 pg/mL, vs. control group 91 ± 76 pg/mL, p<0.001) and significantly increased with the symptoms' severity (Killip class II pts: 6700 ± 1900 pg/mL, Killip class III: 9000 ± 7000 pg/mL, Killip class IV: 29 000 ±7000 pg/mL). All differences were statistically significant (p < 0.01). The cardiothoracic ratio of the patient group was significantly increased compared to controls (0.6 ± 0.1 vs. 0.4 ± 0.1, p<0.001). Linear regression analysis did not show a significant association between NT-proBNP and CTR. The plasma creatinine level in the patient group was significantly elevated compare to the control group (145 ± 45 μmol/l vs. 76 ± 31 μmol/l, p<0.01). Correlation between plasma NT-proBNP and echocardiographic parameters (Tab. 3, Fig. 1-8 ) Left ventricle end-systolic and end-diastolic diameters were significantly positively associated with NT-pro BNP level (r = 0.31, resp. r = 0.54, p<0.01, n 96). LVEF was significantly inversely proportional to NT-proBNP level (r = 0.31; p<0.01, n 96). We also found a significant correlation between NT-proBNP and IVCD (r = 0.51, p<0.01, n 96) and NT-proBNP and plasma creatinine (r = 0.53, p<0.01, n 96). Other parameters (LVMI, LAD, RVID and CTR) were without significant correlation with NT-proBNP.
Evaluation of the echocardiographic parameters
Multivariate linear regression analyses
We performed multiple regression analysis with the aim to evaluate potential confounding factors (age, gender, previous history of heart disease, diabetes mellitus, smoking, hypercholestrolemia) that might significantly contribute to 
Tab. 2:
Characteristics of the controls and subgroups of study population.
Tab. 3:
Relationship between NT-probrain natriuretic peptide, cardiothoracic ratio, echocardiographic parameters and plasma creatinine level in patients with heart failure at the time of admission. NT-proBNP elevation and inferior vena cava diameter. We found significant associations in both IVCD and the female gender (p<0.05), and the association of NT-proBNP with creatinine levels (p<0.01) and previous history of heart failure (p<0.05).
NT-proBNP
Discussion
Our study has shown that: (1) acute heart failure was accompanied with significant changes in non-invasive parameters of heart failure (cardio-thoracic ratio, end-systolic and end-diastolic diameters of the left ventricle, left atrium diameter, right ventricle diameter, the decrease in ejection fraction of the left ventricle), (2) the most significant changes were found in NT-proBNP levels. Furthermore, (3) the plasma NT-proBNP correlates not only with left ventricle ejection fraction plasma creatinine level, but also with the inferior vena cava diameter.
Our study was performed as a pilot study and has some limitations: the circulating concentrations of natriuretic peptides are regulated or modified by several physiologic factors, such as circadian variations, age, gender, eating habits, sodium intake and drugs, including diuretics, angiotensin-converting enzyme inhibitors, adrenergic agonists and antagonists. To eliminate the influence of medication the blood samples were taken at the time of admission. Potential confounders weer evaluated with multiple regression analysis.
The previous studies have shown the correlation between ejection fraction of the left ventricle and plasma natriuretic peptide levels (3, 4, 14, 15, 22) . In our study, we found significant inverse correlation between NT-proBNP and left ventricular ejection fraction.
The increase in both left ventricle diameters can be explained by volume and pressure overload of the left ventricle. In this study we observed that inferior vena cava (IVC) diameter was increased in all patients at the time of admission. It has been shown, that inferior vena cava diameter can reflect volume overload. Recent studies have shown that plasma natriuretic peptide levels can be influenced by left ventricle hypertrophy. Yamamoto et al. (24) showed the slight but significant increase in plasma natriuretic peptide levels in patients with left ventricle hypertrophy and hypertrophic cardiomyopathy. In our study, the increase in plasma NT-proBNP level was extremely high, and we did not find any significant association between plasma NT-proBNP levels and the left ventricle mass index.
The potential clinical use of assays for natriuretic peptides (especially BNP and NT-proBNP) for detection of left ventricular systolic and/or diastolic dysfunction has been confirmed more recently (5, 23, 25) . The ESC Guidelines for diagnosis and treatment of chronic heart failure recommend that cardiac natriuretic peptide assessment should be included in the first step of the algorithm for the diagnosis of HF along with electrocardiography and chest x-rays. According to these guidelines, negative natriuretic peptide level makes diagnosis of heart failure unlikely.
We can conclude that the assessment of plasma NTproBNP level is a relatively simple test which can emerge as a better marker for the assessment of both heart failure severity and risk stratification in acute heart failure patients.
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